The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.
 
Isabelle Laure Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; DECIPHERA; Genmab; GlaxoSmithKline; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Blueprint Medicines; BMS; Bristol-Myers Squibb; Clovis Oncology; Daichi; Deciphera; Eisai; Genmab; GlaxoSmithKline; Macrogenics; Mersana; MSD Oncology; Novartis; Novocure; Ose pharma; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES
 
Marie-Christine Kaminsky-Forrett
No Relationships to Disclose
 
Ryotaro Ohkuma
No Relationships to Disclose
 
Aymeric De Montfort
No Relationships to Disclose
 
Florence Joly
Consulting or Advisory Role - 3A Pharmaceuticals & Diagnostics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; GlaxoSmithKline; Ipsen; Janssen; MSD Oncology; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca; BMS; Eisai; GlaxoSmithKline; Ipsen; Janssen; MSD Oncology
 
Isabelle Treilleux
No Relationships to Disclose
 
Sarah Ghamry-Barrin
No Relationships to Disclose
 
Diana Bello-Roufai
Travel, Accommodations, Expenses - daiichi sankyo; Lilly
 
Pierre Saintigny
Honoraria - Archer; Bristol Myer Squibb; HTG Molecular Diagnostics; Inivata; Roche Molecular Diagnostics
Research Funding - AstraZeneca; BMS Foundation; Illumina; Novartis; Omicure (Inst); Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol Myer Squibb; Illumina; Roche
 
Antoine Angelergues
Honoraria - GlaxoSmithKline
 
Lucas Michon
No Relationships to Disclose
 
Anne-Claire Hardy-Bessard
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; MSD; Novartis; Pfizer; Seagen
 
Alexandra Lainé
No Relationships to Disclose
 
Aude-Marie Savoye
No Relationships to Disclose
 
Justine Berthet
No Relationships to Disclose
 
Christophe Caux
No Relationships to Disclose
 
Fabrice Lecuru
Travel, Accommodations, Expenses - MSD
 
Bertrand Dubois
No Relationships to Disclose
 
Sarah Lagarde Bétrian
No Relationships to Disclose